Skip to content

US · MBX · BIOTECHNOLOGY

MBX Biosciences, Inc. Common Stock (MBX) intrinsic value and stock valuation

$49.55as of 2026-11-21 · Mkt cap 3.21B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

MBX Biosciences, Inc. Common Stock DCF and intrinsic value

InvestorsCraft values MBX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MBX’s statements →

MBX Biosciences, Inc. Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Carmel, IN 46032 mbxbio.com

How the business is doing

Fiscal 2022–2025, USD

Revenue
$0.00
20222025
Net income
-$-86.97M
20222025
Free cash flow
-$-81.88M
20222025
Total equity
$369.2M
20222025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2022–2025, USD
2025202420232022
Revenue$0.00$0.00$0.00$0.00
Operating income-$-98.06M-$-68.19M-$-35.31M-$-25.16M
Net income-$-86.97M-$-61.92M-$-32.56M-$-26.14M
EPSd-$-2.38M-$-1.85M-$-1.02M-$-820.72K
Operating cash flow-$-79.95M-$-54.68M-$-31.98M-$-23.12M
Capital expenditure-$-1.93M-$-870K-$-130K-$-440K
Free cash flow-$-81.88M-$-55.55M-$-32.11M-$-23.56M
Total assets$385.1M$268.5M$84.2M$45.1M
Total debt$600K$170K$320K$460K
Net debt-$-74.69M-$-49.18M-$-30.2M-$-23.75M
Total equity$369.2M$257.4M-$-72.47M-$-42.6M
Cash and short-term investments$373.7M$262.2M$80.7M$42.5M
Income statement
2025202420232022
Revenue$0.00$0.00$0.00$0.00
Cost of revenue$250K$0.00$0.00$0.00
Gross profit-$-250K$0.00$0.00$0.00
Research and development expenses$79.2M$57.4M$28.5M$21.4M
Selling, general and administrative expenses$18.9M$10.8M$6.78M$3.76M
Other expenses$0.00$0.00$0.00$0.00
Operating expenses$98.1M$68.2M$35.3M$25.2M
Cost and expenses$98.1M$68.2M$35.3M$25.2M
Interest income$11.1M$6.27M$2.75M$370K
Interest expense$0.00$0.00$0.00$370K
Depreciation and amortization$250K$240K$160K$60K
Ebitda-$-86.72M-$-61.68M-$-32.41M-$-25.7M
Operating income-$-98.06M-$-68.19M-$-35.31M-$-25.16M
Total other income/expenses, net$11.1M$6.27M$2.75M-$-970K
Income before tax-$-86.97M-$-61.92M-$-32.56M-$-26.14M
Income tax expense$0.00$0.00$0.00$0.00
Net income-$-86.97M-$-61.92M-$-32.56M-$-26.14M
Weighted average shares outstanding$36.5M$33.4M$31.9M$31.9M
Weighted average diluted shares outstanding$36.5M$33.4M$31.9M$31.9M
Balance sheet
2025202420232022
Cash and short-term investments$373.7M$262.2M$80.7M$42.5M
Net receivables$2.12M$680K$210K$140K
Inventory$0.00$0.00$0.00$0.00
Total current assets$381.5M$267.3M$83.5M$44.2M
Property, plant and equipment, net$3.22M$1.2M$670K$840K
Goodwill and intangible assets$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00
Total non-current assets$3.6M$1.25M$710K$880K
Total assets$385.1M$268.5M$84.2M$45.1M
Accounts payable$2.98M$5.33M$1.39M$980K
Short-term debt$170K$170K$150K$140K
Deferred revenue$0.00$0.00$0.00$0.00
Total current liabilities$15.5M$11.1M$3.93M$3.43M
Long-term debt$420K$0.00$170K$320K
Deferred revenue, non-current$0.00$0.00$0.00$0.00
Total non-current liabilities$430K$40K$152.7M$84.3M
Capital lease obligations$170K$170K$320K$460K
Total liabilities$15.9M$11.1M$156.7M$87.7M
Common stock$10K$10K$0.00$0.00
Retained earnings-$-224.48M-$-137.5M-$-75.58M-$-43.02M
Accumulated other comprehensive income (loss)$290K$60K$60K$0.00
Total equity$369.2M$257.4M-$-72.47M-$-42.6M
Total investments$298.4M$212.8M$50.2M$18.3M
Total debt$600K$170K$320K$460K
Net debt-$-74.69M-$-49.18M-$-30.2M-$-23.75M
Cash flow statement
2025202420232022
Net income-$-86.97M-$-61.92M-$-32.56M-$-26.14M
Depreciation and amortization-$-3.61M$240K$160K$60K
Stock-based compensation$8.68M$5.22M$2.04M$310K
Change in working capital$1.57M$4.6M-$-730K$1.29M
Accounts receivable$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Accounts payable-$-2.46M$3.93M$410K$670K
Net cash provided by operating activities-$-79.95M-$-54.68M-$-31.98M-$-23.12M
Investments in property, plant and equipment-$-1.93M-$-870K-$-130K-$-440K
Acquisitions, net$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-83.7M-$-160.59M-$-30.93M-$-11.41M
Common stock issued$189.6M$174.5M$740K$30K
Common stock repurchased$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00
Net cash used for financing activities$189.6M$234.1M$69.2M$46.1M
Net change in cash$25.9M$18.8M$6.31M$11.5M
Cash at end of period$75.3M$49.4M$30.5M$24.2M
Operating cash flow-$-79.95M-$-54.68M-$-31.98M-$-23.12M
Capital expenditure-$-1.93M-$-870K-$-130K-$-440K
Free cash flow-$-81.88M-$-55.55M-$-32.11M-$-23.56M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About MBX Biosciences, Inc. Common Stock

        MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.

        CEO
        Steve Hoerter
        Employees
        63
        Beta
        0.10

        Explore

        Frequently asked questions

        What is the intrinsic value of MBX Biosciences, Inc. Common Stock (MBX)?

        InvestorsCraft does not currently publish an intrinsic value for MBX. How the IC value is calculated.

        Is MBX undervalued?

        InvestorsCraft does not publish an undervaluation signal for MBX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.